Completed PHASE3 INTERVENTIONAL NCT00252707

Iressa 2nd Line Phase III Study in Japan

A Multicentre, Randomised, Open-Label, Parallel-Group, Phase III Post-Marketing Clinical Study to Compare the Overall Survival Between Gefitinib and Docetaxel in Patients With Advanced or Metastatic (Stage IIIB/IV), or Recurrent Non-Small Cell Lung Cancer, Who Have Failed One or Two Chemotherapy Regimens

Sponsor: AstraZeneca

Conditions Non-Small Cell Lung Cancer

Interventions Gefitinib or Docetaxel

Updated 7 times since 2017 Last updated: Dec 14, 2007 Started: Sep 30, 2003 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00252707, this PHASE3 trial focuses on Non-Small Cell Lung Cancer and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akashi, Japan , Asahikawa, Japan , Beppu, Japan , Bunkyo-ku, Japan , Chūō, Japan , Fukuoka, Japan , Gifu, Japan , Habikino, Japan , Hirosaki, Japan , Isehara, Japan and 30 more locations